X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1061) 1061
humans (972) 972
deep-vein thrombosis (702) 702
female (456) 456
male (425) 425
thromboembolism (410) 410
molecular-weight heparin (386) 386
peripheral vascular disease (352) 352
risk factors (351) 351
anticoagulants - therapeutic use (343) 343
pulmonary embolism (338) 338
venous thromboembolism (334) 334
hematology (333) 333
pulmonary-embolism (320) 320
deep vein thrombosis (312) 312
middle aged (312) 312
prevention (300) 300
surgery (299) 299
aged (293) 293
venous thrombosis (274) 274
deep venous thrombosis (272) 272
adult (258) 258
thrombosis (234) 234
anticoagulants (228) 228
prophylaxis (186) 186
venous thrombosis - prevention & control (185) 185
abridged index medicus (168) 168
diagnosis (166) 166
treatment outcome (161) 161
venous thrombosis - etiology (158) 158
aged, 80 and over (142) 142
venous thrombosis - drug therapy (142) 142
heparin (140) 140
medicine & public health (140) 140
incidence (136) 136
heparin, low-molecular-weight - therapeutic use (131) 131
orthopedics (126) 126
unfractionated heparin (123) 123
thromboembolism - prevention & control (120) 120
anticoagulants - administration & dosage (118) 118
pulmonary embolism - prevention & control (116) 116
postoperative complications - prevention & control (112) 112
pulmonary embolism - etiology (112) 112
animals (105) 105
risk-factors (105) 105
care and treatment (104) 104
medicine, general & internal (104) 104
prospective studies (104) 104
risk (102) 102
venous thrombosis - epidemiology (102) 102
risk assessment (100) 100
venous thrombosis - diagnosis (100) 100
venous thrombosis - diagnostic imaging (100) 100
retrospective studies (99) 99
health aspects (98) 98
d-dimer (97) 97
venous thromboembolism - prevention & control (97) 97
anticoagulants - adverse effects (92) 92
fibrinolytic agents - therapeutic use (90) 90
thromboprophylaxis (88) 88
time factors (88) 88
pulmonary embolism - diagnosis (87) 87
ultrasonography (86) 86
venous thromboembolism - etiology (85) 85
heparin - therapeutic use (82) 82
enoxaparin (81) 81
total hip-replacement (81) 81
warfarin (81) 81
drug therapy (79) 79
analysis (78) 78
cancer (76) 76
venous thrombosis - therapy (76) 76
cardiac & cardiovascular systems (75) 75
double-blind (75) 75
vein thrombosis (75) 75
complications (74) 74
pharmacology & pharmacy (73) 73
adolescent (72) 72
anticoagulation (72) 72
low-dose heparin (72) 72
therapy (72) 72
mortality (71) 71
thrombolytic therapy (70) 70
thromboembolism - etiology (68) 68
postthrombotic syndrome (65) 65
pregnancy (64) 64
management (63) 63
blood clot (62) 62
respiratory system (62) 62
pulmonary embolism - epidemiology (61) 61
critical care medicine (60) 60
oncology (60) 60
research (59) 59
venous thrombosis - complications (59) 59
blood clots (57) 57
catheter-directed thrombolysis (56) 56
pulmonary embolism - drug therapy (56) 56
total knee arthroplasty (56) 56
veins & arteries (56) 56
acute disease (54) 54
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Deep vein thrombosis in Indian patients undergoing major lower limb surgery, 12/2003
Thromboembolism remains a major preventable cause of postoperative mortality and morbidity in the Western world; very little attention has been given to this... 
Deep vein thrombosis, low molecular weight heparin, thrombi
Journal
EUROPEAN HEART JOURNAL, ISSN 0195-668X, 09/2008, Volume 29, Issue 18, pp. 2276 - 2315
Journal Article
Journal Article
Journal of Vascular Surgery, ISSN 0741-5214, 1998, Volume 28, Issue 1, pp. 67 - 74
Journal Article
Thrombosis Research, ISSN 0049-3848, 2012, Volume 131, Issue 1, pp. e31 - e38
Abstract Objective The experiment was designed to analyze whether and how Nitric Oxide (NO) microbubbles facilitates deep vein thrombosis (DVT) resolution in a... 
Hematology, Oncology and Palliative Medicine | Deep vein thrombosis | Microbubbles | Rat model | Thrombolysis | Nitric oxide | Coagulation | NITRIC-OXIDE SYNTHASE | RIVAROXABAN | VENOUS THROMBOSIS | ARTERIAL THROMBOSIS | ADHESION MOLECULES | KNEE REPLACEMENT | ULTRASOUND | TOTAL HIP | MOLECULAR-WEIGHT HEPARIN | MOUSE MODEL | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | Immunohistochemistry | Vena Cava, Inferior - surgery | Fibrinolytic Agents - chemistry | Injections, Intravenous | Iliac Vein - surgery | Prothrombin Time | Venous Thrombosis - blood | Male | RNA, Messenger - metabolism | Drug Carriers | Lipids - chemistry | Matrix Metalloproteinase 9 - metabolism | Thrombomodulin - metabolism | Ligation | Time Factors | Matrix Metalloproteinase 9 - genetics | Nitric Oxide Synthase Type III - metabolism | Thrombomodulin - genetics | Real-Time Polymerase Chain Reaction | Disease Models, Animal | Thrombin Time | Nitric Oxide - chemistry | Venous Thrombosis - drug therapy | Endothelial Cells - metabolism | Matrix Metalloproteinase 2 - metabolism | Gene Expression Regulation | Rats | Nitric Oxide - administration & dosage | Nitric Oxide Synthase Type III - genetics | Rats, Sprague-Dawley | Blotting, Western | Venous Thrombosis - etiology | Vascular Cell Adhesion Molecule-1 - blood | Matrix Metalloproteinase 2 - genetics | Animals | Partial Thromboplastin Time | Fibrinogen - metabolism | Fibrinolytic Agents - administration & dosage | Venous Thrombosis - genetics | Venous Thrombosis - pathology | Endothelial Cells - pathology | Endothelial Cells - drug effects | Pulmonary embolism | Fibrin | Medical examination | Blood coagulation factors | Polyols | Blood | Index Medicus
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 7/2013, Volume 72, Issue 1, pp. 65 - 73
Whether an anticoagulant prophylaxis is needed for patients with cancer with a central venous catheter is a highly controversial subject. We designed a study... 
LMWH | Catheter-related thromboembolism | Medicine & Public Health | Prophylaxis | Oncology | Cancer Research | Pharmacology/Toxicology | Cancer | RISK-FACTORS | ACCESS DEVICES | PREVENTION | PROSPECTIVE TRIAL | DALTEPARIN | CHEMOTHERAPY | ONCOLOGY | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | THROMBOEMBOLISM | THROMBOPROPHYLAXIS | CENTRAL VENOUS CATHETERS | Anticoagulants - administration & dosage | Humans | Middle Aged | Heparin, Low-Molecular-Weight - adverse effects | Upper Extremity Deep Vein Thrombosis - prevention & control | Warfarin - adverse effects | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Venous Thrombosis - complications | Heparin, Low-Molecular-Weight - therapeutic use | Warfarin - administration & dosage | Incidence | Warfarin - therapeutic use | Young Adult | Neoplasms - complications | Upper Extremity Deep Vein Thrombosis - epidemiology | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Venous Thrombosis - prevention & control | Severity of Illness Index | France - epidemiology | Lost to Follow-Up | Upper Extremity Deep Vein Thrombosis - physiopathology | Anticoagulants - therapeutic use | Central Venous Catheters - adverse effects | Venous Thrombosis - physiopathology | Upper Extremity Deep Vein Thrombosis - etiology | Anticoagulants - adverse effects | Neoplasms - drug therapy | Medication Adherence | Venous Thrombosis - epidemiology | Intention to Treat Analysis | Aged | Medical colleges | Cancer patients | Care and treatment | Warfarin | Chemotherapy | Catheterization | Clinical trials | Dosage and administration | Thromboembolism | Medical imaging equipment | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2011, Volume 364, Issue 14, pp. 1305 - 1314
Journal Article
Journal Article